Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis

NCT07388420 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hypertriglyceridemia Induced Acute Pancreatitis

Interventions

DRUG: Evolocumab 140 MG/ML [Repatha]
DRUG: Conventional lipid-lowering therapy

Sponsor

General Hospital of Shenyang Military Region